Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203287 · ClinicalTrials.gov registry record · Phase 4
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
A Phase 4 study of Neuromuscular Blockade and General Anesthesia, sponsored by The University of Texas Medical Branch, Galveston.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 490
- Enrollment target
- 1
- Study location
NCT07203287 is a Phase 4 study of Neuromuscular Blockade and General Anesthesia that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 490 participants, below the 11,759-participant average among 6 other Neuromuscular Blockade trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07203287, a Phase 4 study of Neuromuscular Blockade and General Anesthesia, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 490 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Conditions Studied
Interventions
- DRUG Rocuronium
- DRUG Cisatracurium
- DRUG Sugammadex
- DRUG Neostigmine
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2027-08-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07203287
The ClinicalTrials.gov registry entry for NCT07203287 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,759-participant average among 6 other Neuromuscular Blockade trials with a reported enrollment target (96% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neuromuscular Blockade appearing as the primary indexed condition, and to 4 interventions - of which Rocuronium is the first listed.
NCT07203287 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07203287 about?
NCT07203287 is a clinical study titled "Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease". The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pu...
What is the current status of trial NCT07203287?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 490 participants. The study started on 2025-08-26. Estimated completion is 2027-08-26.
What conditions does trial NCT07203287 study?
This clinical trial studies the following conditions: Neuromuscular Blockade, General Anesthesia, Post Operative Pulmonary Complications.
What interventions are being tested in trial NCT07203287?
The interventions under investigation include: Rocuronium (DRUG), Cisatracurium (DRUG), Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT07203287?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203287 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromuscular Blockade
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
COMPLETED · Phase 4
-
The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
COMPLETED · Phase 4
-
Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison
RECRUITING
-
NMBA Reversal and Postoperative Urinary Retention
ACTIVE NOT RECRUITING
-
Understanding the Cognition and Decision Making of Community Anesthesiologists
COMPLETED
-
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.